177Lu-RAYZ-6283

N/A

Report date: 2025/11/20 16:04:32
First In Class

Base Information

Drug Name177Lu-RAYZ-6283
Drug Alias Name177Lu-RAYZ-6283177-Lu-RAYZ-6283
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionEphrin type-A receptor 2 modulators
TargetsEphrin type-A receptor 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRayzeBio IncPeptiDream Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeptiDream IncRayzeBio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A